A review of the investigational antiarrhythmic agent dronedarone

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 12, Issue 1, 2007, Pages 15-26

  Tafreshi, Mohammad J ^a   Rowles, Joie ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Amiodarone; Antiarrhythmic; Atrial fibrillation; Dronedarone; Investigational

Indexed keywords

ADRENERGIC RECEPTOR; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DILTIAZEM; DOFETILIDE; DRONEDARONE; FLECAINIDE; LIDOCAINE; METOPROLOL; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; VERAPAMIL;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DIARRHEA; DRUG FATALITY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSTHYROID; ELECTROPHYSIOLOGY; EXTRASYSTOLE; GASTROENTERITIS; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART PROARRHYTHMIA; HEART RHYTHM; HUMAN; INCIDENCE; ION CURRENT; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SKIN DISEASE; SUPRAVENTRICULAR TACHYCARDIA; THROMBOSIS; THYROID DISEASE; TORSADE DES POINTES; VOMITING;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; ION CHANNELS; MEMBRANE POTENTIALS; MOLECULAR STRUCTURE;

EID: 34247575095     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406299069     Document Type: Review

References (46)

1. Kodama I., Kamiya K., Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997 ; 35: 13-29.
2. Doggrell SA Amiodarone: waxed and waned and waxed again. Expert Opin Pharmacother. 2001 ; 2: 1877-1890.
3. Camm J. Pharmacologic management of atrial fibrillation: where do we currently stand ? Medscape Cardiol. 2005 ; 9: 2.
4. Vorperian VR, Havighurst TC, Miller S., et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997 ; 30: 791-798.
5. Braunwald E. Shattuck Lecture: cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997 ; 337: 1360-1369.
6. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. JAMA. 2001 ; 285: 2370-2375.
7. Tsang Tsm, Gersh BJ Atrial fibrillation: an old disease, a new epidemic. Am J Med, 2002 ; 113: 432-435.
8. Wolf PA, Abbott RD, Kannel WB Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991 ; 22: 983 - 988.
9. Benjamin EJ, Wolf, PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation. 1998 ; 98: 946-952.
10. Stewart S., Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002 ; 113: 359-364.
11. Feinberg WM, Blackshear JL, Laupacis A., et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995 ; 155: 469-473.
12. Singh BN Atrial fibrillation: epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm. J Cardiovasc Pharmacol Therapeut. 2003 ; 8: S13 - S26.
13. AFFIRM Investigators. A Comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 ; 347: 1825-1833.
14. Vidaillet HJ Rate control vs. rhythm control in the management of atrial fibrillation in elderly persons. Am J Geriatr Cardiol. 2005 ; 14: 73-78.
15. Hancox JC, Patel Kcr, Jones JV Antiarrhythmics- from cell to clinic: past, present, and future. Heart. 2000 ; 84: 14-24.
16. Nattel S. Atrial electrophysiology and mechanism of atrial fibrillation. J Cardiovasc Pharmacol Therapeut. 2003 ; 8: S5 - S11.
17. Singh BN, Sarma Jsm. Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias. J Cardiovasc Pharmacol Therapeut. 2001 ; 6: 69-87.
18. Lee K., Park JY, Ryu PD, Kwon LS, Kim HY IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents. 2003 ; 1: 203-223.
19. Elming H., Brendorp B., Pehrnos S., Pedersen OD, Kober L., Torp-Petersen C. A benefit-risk assessment of class III antiarrhythmic agents. Expert Opin Drug Saf. 2004 ; 3: 559-577.
20. Lombardi F., Terranova P. Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs. Curr Med Chem. 2006 ; 13: 1635-1653.
21. Sun W., Sarma Jsm, Singh BN Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation. 1999 ; 100: 2276-2281.
22. Sun W., Sarma Jsm, Singh BN Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol. 2002 ; 39: 677-684.
23. Varro A., Takacs J., Nemeth M., et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol. 2001 ; 133: 625-634.
24. Gautier P., Guillemare E., Marion A., et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol. 2003 ; 41: 191-202.
25. van Opstal JM, Schoenmakers M., Verduyn SC et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001 ; 104: 2722-2727.
26. Chatelain P., Meysmans L., Matteazzi JR, et al. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol. 1995 ; 116: 1949-1956.
27. Hodeige D., HeyndrickxJ-P, Chatelain P, Manning A. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol. 1995 ; 279: 25-32.
28. Lalevee N., Barrere-Lemaire S., Gautier P., et al. Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol. 2003 ; 14: 885-890.
29. Snyders D. Structure and function of cardiac potassium channels. Cardiovasc Res. 1999 ; 42: 377-390.
30. Deal KK, England SK, Tamkun MM Molecular physiology of cardiac potassium channels. Physiol Rev. 1996 ; 76: 49-67.
31. Tamargo J., Caballero R., Gomez R., et al. Pharmacology of cardiac potassium channels. Cardiovasc Res. 2004 ; 62: 9-33.
32. Ridley JM, Milnes JT, Witchel, HJ, Hancox, JC. High affinity HERG K+ channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem Biophys Res Commun. 2004 ; 325: 883-891.
33. Aimond F., Beck L., Gautier P., et al. Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats. J Pharmacol Exp Ther. 2000 ; 292: 415-424.
34. Watanabe Y., Hara, Y., Tamagawa M., Nakaya, H. Inhibitory effect of amiodarone on the muscarinic acetylcholine receptor-operated potassium current in guinea pig atrial cells. J Pharmacol Exp Ther. 1996 ; 279: 617-624.
35. Altomare C., Barbuti A., Viscomi C., et al. Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells. Br J Pharmacol. 2000 ; 130: 1315-1320.
36. Guillemare E., Marion A., Nisato D., Gautier P. Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells. J Cardiovasc Pharmacol. 2000 ; 36: 802-805.
37. Kathofer S., Thomas D., Karle C. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev. 2005 ; 23: 217-230.
38. Hynes BJ, Luck JC, Wolbrette DL, et al. A review of the pharmacokinetics, electrophysiology and clinical safety of dronedarone. Future Cardiol. 2005 ; 1: 135-144.
39. Touboul P., Brugada J., Capucci A., et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003 ; 24: 1481-1487.
40. Schellekens S., Verheugh Fwa. Hotline sessions of the 26th European congress of cardiology. Eur Heart J. 2004 ; 25: 2164-2166.
41. Hohnloser SH, Klinikum Der. Dronedarone significantly decreases the combined endpoint of hospitalization and death in patients with atrial fibrillation. American Heart Associations Scientific Sessions 2005, poster 1637. http://aha.scientificposters.com/postersearch.cfm.
42. Davy J. Dronedarone demonstrates additional rate control on top of standard pharmacotherapies in the treatment of atrial fibrillation. American Heart Associations Scientific Sessions 2005, poster 2737. Available at: http://aha.scientificposters.com/postersearch.cfm.
43. Pantos C., Mourouzis, I., Malliploulou V., et al. Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor 1. Thyroid. 2005 ; 15: 16-23.
44. van Beeren HC, Jong, Wmc, Kaptein E., et al. Dronedarone acts as a selective inhibitor of 3,5,3 -triiodothyronine binding to thyroid hormone receptor1: in vitro and in vivo evidence. Endocrinology. 2003 ; 144: 552-558.
45. Quaglino D., Ha HR, Duner E., et al. Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship. Am J Physiol Lung Cell Mol Physiol. 2004 ; 287: L438 - L447.
46. Tschuppert Y., Buclin T., Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Clin Pharmacol Ther. 2005 ; 2: P10, PI-9.